INTRODUCTION
children with high-grade CNS tumors will go on to experience recurrence or progression, and the likelihood of this will depend on the histology and location of their first tumor, as well as treatments given. 1, 2 In recent years, magnetic resonance imaging (MRI) has become the predominant imaging tool in the management of children with highgrade CNS tumors. The rationale behind routine imaging, or surveillance, is that recurrence or progressive disease detected at an earlier stage may be more responsive to treatment and benefit from a wider range of treatment options than disease diagnosed at a later stage from clinical signs and symptoms. However, no consensus has been reached as to whether this leads to improved outcomes for patients and their families.
The objectives of this review were therefore to:
1. assess the diagnostic utility of surveillance MRI in detecting tumor recurrence prior to the emergence of new clinical signs and symptoms compared with the non-routine use of MRI upon symptomatic presentation and assess whether this practice translates to measurable improvements in clinical outcomes;
2. consider the effect of differing screening intervals on the diagnostic utility of surveillance MRI and determine the optimal duration of imaging after initial diagnosis; and 3. identify any gaps and methodological weaknesses in the current evidence base and make recommendations to inform the design and analysis of future studies.
The authors have also undertaken a systematic review on the effectiveness of surveillance MRI in pediatric low-grade tumors, which forms a companion piece to this review paper. 3 
METHODS
Standard systematic review methodology was employed and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 4 A detailed account of the methodology employed in this review can be found in the published protocol, which is also registered with PROSPERO (CRD 42016036802). 5 A summary of the methods is described below.
Search strategy
This review formed part of a wider NIHR-funded work program of systematic reviews aimed at assessing the effects of different interventions for the treatment of pediatric CNS tumors and therefore searches were not restricted to studies concerned solely with surveillance imaging in children with high-grade tumors. Searches for published studies from 1985 to August 2018 were undertaken in several databases, including MEDLINE and EMBASE (see Supporting Information File S1). No language, publication restrictions, or study design filters were applied.
Study selection
The following inclusion and exclusion criteria were applied:
Population: Children and young adults (up to age 25 years) with diagnoses of any type of high-grade CNS tumor who were asymptomatic at the time of study recruitment. Given that children undergoing surveillance may have some neurologic sequelae from their tumor and/or its treatment, it would be more accurate to characterize patients as exhibiting no new, stable, or improved neurological signs or symptoms.
Interventions: Routine or surveillance MRI. Studies employing computed tomography (CT) as the sole surveillance imaging modality were excluded.
Outcome measures: These included recurrence rates (by study, tumor type, location, and extent of resection), diagnostic yield of imaging, timing of recurrence, change in patient management postrecurrence, overall survival (OS), surrogate survival measures (e.g., recurrencefree survival, progression-free survival (PFS)), and quality of survival.
Studies reporting outcomes from aggregated CT and MRI scans were excluded.
Study designs:
As randomized controlled trials (RCTs) and nonrandomized comparative studies were initially sought but not identified, the review was extended to include observational studies such as case series.
Study selection was undertaken by two independent reviewers, with disagreements resolved by discussion.
Data extraction and risk of bias assessment
Data, extracted by one reviewer and checked by a second, were recorded on a standardized proforma developed in Microsoft Word (see Supporting Information File S2). Risk of bias was assessed at the study level by two reviewers using a six-point tool devised by the Centre for Reviews and Dissemination (York; CRD) 6 designed to assess bias in case series studies.
Statistical analysis
Due to the design of the included studies and the heterogeneity of outcomes reported, only a descriptive analysis was undertaken.
RESULTS

Quantity and description of included studies
From the electronic database searches, 28 potentially relevant publications were identified, with an additional 13 publications identified from citation-checking. On full-text examination, 38 were excluded, including 11 studies that employed both CT and MRI as surveillance imaging modalities but failed to report results separately for MRI (see Supporting Information File S3). No RCTs or prospective comparative studies were identified. Three retrospective case series studies [7] [8] [9] were included in the review (see Figure 1) . Table 1 ).
Quality of the research
Studies were clinically heterogeneous with study populations varying in terms of both tumor type and disease severity. Study samples were small but patients appeared to be representative of the target population, although it was unclear whether patients were at a similar time point in the disease progression. Inclusion and exclusion criteria for each study were explicitly stated. Generally, details of previous treatments were not reported (see Supporting Information File S4). There was also variability in terms of reporting and defining of outcomes. The terms "recurrence" and "progression" were defined in all three studies, although only two reported recurrences as "symptomatic" and "asymptomatic" and defined these terms. 7, 9 All three studies reported OS, although only Kornreich 8 defined the term (see Supporting Information Table S5 ). This was also the only study to report PFS. Korones and symptomatic recurrences comparable in number, although the numbers in each category were very small (ranging from 1 to 6) (see Table 2 ). Recurrence by extent of resection was not reported.
The diagnostic yield of imaging for all 17 asymptomatic patients was 4.4%, i.e., one asymptomatic recurrence detected every 23 MRI scans (see Table 2 ). With respect to choroid plexus carcinoma (CPC), germ cell tumor (GCT), and AT/RT, there were two asymptomatic recurrences among these tumor types, and the diagnostic yield of imaging was 6.5%. • Image sequences taken: No details.
• Imaging schedule: 1 scan every 2.5 months (range, 1/1 month to 1/6.7 months).
• Average number of MRI images per patient: NR for high-grade tumor patients only. • Image sequences taken: All patients underwent at least T1-weighted (T1W) sagittal and T1W and T2W axial sequences, with contrast agent (gadopentate dimeglumine) used in all cases.
• Progression rate
• Medium time to progression
• Median OS
• Median PFS
• Tumor response rates
• Changes in patient treatment due to progression (Continues) • No details of the MRI scanner used or the image sequences taken.
• Median follow-up; total and by tumor type
• Median number of scans (range); total and by tumor type
• Recurrence rate; total and by tumor type, and by first and subsequent recurrences
• Symptomatic status at recurrence
• Median time to recurrence; total and by tumor type, and by symptomatic status at recurrence
• Median OS by symptomatic status at recurrence
• Frequency of MRI-detected recurrence; total and by tumor type Abbreviations: asymp, asymptomatic; DIPG, diffuse pontine glioma; epend, ependymoma; GCT, germ cell tumor; HGG, high-grade glioma; MB, medulloblastoma; N, number of patients; sPNET, supratentorial primitive neuroectodermal tumor; symp, symptomatic. a As of 2016, the term PNET no longer appears in the current WHO classification of CNS tumors. b "Other" includes choroid plexus carcinoma (n = 1), germ cell tumor (n = 1), and atypical teratoid/rhabdoid tumor (n = 1). c Asymptomatic recurrence only.
recurrence. Median OS was 1.67 years, with three patients (20%) alive atthetimeofreporting.
3.3.3
Perreault (2014) 9 Perreault 9 was a retrospective case series study that sought to assess the benefits of surveillance MRI in a cohort of 258 high-grade tumor patients. Seven tumor types were included (see Table 1 ). All patients underwent surgery as the primary treatment, although this was not further specified by extent of resection. At commencement of surveillance imaging, none of the patients had relapsed disease.
Although frequency of scanning was not reported, the median number of MRI scans per patient across all tumor types was 13, 10 of the brain and three spinal (see Table 3 ). The interval since last MRI for symptomatic patients was not longer for symptomatic compared with asymptomatic patients (mean, 3.9 vs
months).
Rates of recurrence/progression were also reported by symptomatic status (see Table 3 ). With respect to first recurrences (n = 113), there was a slight predominance of asymptomatic (46%) compared with symptomatic recurrences (42%), whereas for subsequent recurrences (n = 125) the converse was the case (29% vs 58%).
Recurrences ( Table 3 ).
The median time to recurrence from initial diagnosis was 1 year, although it is unclear whether this relates to first recurrence or all recurrences. The median time to recurrence by tumor type was reported but, again, it is unclear if this relates to first recurrence or all recurrences (see Table 3 ). No significant difference in median time to recurrence was reported between symptomatic and asymptomatic patients at recurrence (1.0 and 0.92 years, respectively;
The time by which greater than 90% of recurrences had occurred for each individual tumor type was also reported (see Table 3 ). Median time to recurrence by extent of resection was not reported.
Change in patient management following first recurrence was reported for 93% of patients, with 59% of patients undergoing new treatments, 11% continuing with existing treatment, 16% scheduled for palliative care, and 7% undergoing closer interval surveillance MRI. New treatments consisted of chemotherapy (22% standard dose and 4% high dose with stem cell support), radiotherapy (6%), radiosurgery (2%), surgery (5%), and unspecified multimodal therapy (20%).
Change in patient management postrecurrence by tumor type was not reported.
There was no significant difference (P > 0.3) in median OS from recurrence between symptomatic and asymptomatic patients (1.92 and 2.25 years, respectively). Median OS by tumor type was not reported.
TABLE 3
Summary of radiographic outcomes by tumor type in Perreault 9 First recurrence (n (46) 47 (42) 14 (12) 36 (29) 58 (46) 31 (25) 8. 17 (63) 6 (22) 4 (15) 6 (21) 12 (41) 11 (38) 5. (46) 7 (27) 7 (27) 10 (26) 15 (38) 14 (36) 11. 19 (68) 2 (7) 5 (19) 19 (73) 2 (8) 21 8 (57) 1 (7) 11 (58) 6 (32) 2 (10) 10.5 
DISCUSSION
This systematic review is one of a series evaluating treatments for children with CNS tumors. Underpinning the reviews was consultation with clinical experts and a patient and public involvement (PPI) group, consisting of mothers of children with CNS tumors. The PPI group in particular expressed concerns about overscanning, especially in situations where scanning is no longer able to influence prognosis as in the case of patients for which nothing further can be clinically done.
As well as the unknown risks associated with repeated administration of contrast materials such as gadolinium, 10 anesthesia, and sedatives, the PPI group spoke of what has come to be termed "scanxiety," i.e., an overwhelming feeling of stress experienced by both patient and family asymptomatic recurrence rates were higher for ependymoma and medulloblastoma compared with other tumor types, suggesting that surveillance might potentially be beneficial to these patients, although in this study asymptomatic patients across all tumor types did not benefit from improved OS compared with symptomatic patients.
Unfortunately, the potential for bias within case series is considerable, and therefore conclusions from this review are tentative and should be viewed with extreme caution. important to appreciate that the data analyzed in these studies were acquired for clinical purposes for which assessment of surveillance imaging protocols was not an objective.
The initial aim of this review was to assess the effectiveness of surveillance MRI. RCTs were required to do this, but as none were found, the focus was switched to finding studies that were specifically conducted to describe surveillance scanning. With just three studies meeting the inclusion criteria, one criticism of this review that emerged from the peer review process was that the cooperative trials should have been hand-searched for information on surveillance. This raises an interesting point about the best way to systematically review pediatric oncology trials. Systematic reviewing (especially employing Cochrane methodology) was developed with single-question trials involving more common diseases in mind, i.e., A versus B, whereas pediatric oncology trials tend to be cooperative, multimodal trials that attempt to answer a variety of questions within a single trial due to the rarity of the diseases. In response to the peer review feedback, a search of cooperative trials in medulloblastoma was undertaken to determine whether there were data within these trials to inform the review question. Of 27 trials, surveillance MRI scanning intervals appeared to be arbitrary and variable, with few reasons given for the surveillance schedules (see Supporting Information File S6). Only one study, not identified in our systematic review searches likely due to indexing, evaluated the number of patients who had relapse detected through surveillance MRI compared with symptom-based relapse. 22 This study reported that 45 relapses were detected on surveillance MRI, with 20 detected from symptoms alone. Of these, patients detected from symptoms had a significantly shorter survival postrelapse than those detected by surveillance MRI (P < 0.01), although OS postprimary diagnosis was not statistically significantly different. This could be due to lead time bias or that patients in the symptomatic relapse group possibly have more aggressive tumors. Finding the evidence in a systematic way, from identifying the relevant publications to finding the information within the trial publications (often results are written into the discussions) can be challenging in these large cooperative trials. In the future, we recommend that systematic reviewers consider handsearching relevant cooperative trials, while bearing in mind that the main aim of these trials might differ from that of the systematic review.
We also urge authors of cooperative trials to improve the transparency of their publications, especially with respect to database indexing as well as signposting and organization of information within the papers.
The paucity of data evidenced in this review may be due to the complexity of surveillance in these patients, with frequency of monitoring depending on tumor type, disease status (newly diagnosed, resistant or relapsed), extent of metastatic spread, and previous treatments. Other factors such as pseudoprogression and radiation necrosis can also complicate the interpretation of scans, making it a difficult area to investigate. However, there is a need to examine this question further in order to guide clinicians in developing optimal evidence-based surveillance strategies, to help parents and children understand the need for surveillance, and to optimize the use of health service resources. There is a role for researchers to build into future, large cooperative trials methodology that investigates the role of surveillance MRI or, at the very minimum, collects and reports data on the trial surveillance MRI practice, as well as incorporating quality-of-life data collection, particularly regarding anxiety around surveillance and the reassurance that it may also afford.
CONCLUSION
Only three retrospective observational studies with a high risk of bias were identified to guide clinical practice of surveillance MRI for children with high-grade CNS tumors. [7] [8] [9] These studies do not clearly demonstrate benefit or harm for this practice, nor do they define 
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